Lucida Medical today announced that it has signed a distribution agreement with international medical imaging IT and cybersecurity company Sectra. Through this agreement, the Lucida Pi application for diagnosing prostate cancer from MRI images will be offered through the Sectra Amplifier Marketplace. This greatly expands the availability of Pi to assist healthcare by improving the speed and accuracy of prostate cancer diagnosis.

About Sectra

Sectra develops and sells imaging IT solutions. It provides healthcare providers worldwide with enterprise imaging solutions comprising PACS for imaging-intensive departments (radiology, pathology, cardiology, orthopaedics, ophthalmology), and VNA to store all types of medical images and information, as well as solutions for sharing and collaborating around medical imaging.

About Sectra Amplifier Marketplace

The Sectra Amplifier Marketplace aims to accelerate the adoption of AI into clinical practice. The AI applications available at the Sectra Amplifier Marketplace, such as Pi, can be integrated into Sectra’s enterprise imaging solution.

https://amplifiermarketplace.sectra.com/radiology/

About Lucida Medical

Lucida Medical has developed a pioneering AI platform, Pi, with the aim of improving the speed and accuracy of prostate cancer tests. This could help to improve early detection and treatment and reduce the number of cancer-free patients going through more invasive investigative procedures, as well as potentially saving healthcare providers time and money.

Prostate cancer is the most common male cancer in UK men and across the developed world. There are more than 500,000 men living with prostate cancer in the UK[i] and over 50,000 are diagnosed each year[ii]. These numbers are growing and it is estimated that by 2040 there will be 1 million men living with prostate cancer just in the UK[iii] alone. It’s a common misconception that prostate cancer is harmless: while the lowest grades of prostate cancer develop slowly, 12,000 men die from it each year in the UK[iv].

Pi™ is built using Lucida Medical’s proprietary AI technology to identify prostate cancer from MRI scans. Preliminary analysis suggests the software has accuracy comparable to expert radiologists, according to results presented at the 2023 International Cancer Imaging Society annual meeting from a diverse group of six NHS hospitals who are participating in the PAIR-1 clinical study[v].

“Joining the Sectra Amplifier Marketplace will make it simple for Sectra users to adopt the Pi technology, expanding our ability to help healthcare providers diagnose prostate cancer across the UK and Europe”, commented Dr Antony Rix, CEO and co-founder of Lucida Medical.

“We seek to give every radiologist technology that can precisely identify significant cancers, allowing more patients to benefit from early detection and treatment. At the same time, the accuracy of Pi™ could help reduce the numbers of prostate cancer-free men who undergo painful, potentially avoidable investigations, saving the NHS costs and helping address the shortage of radiologists,” commented Prof Evis Sala, Chief Medical Officer and co-founder of Lucida Medical.

More about Lucida Medical

Lucida Medical is a spin out from the University of Cambridge. It was founded in 2019 by Dr. Antony Rix, an expert in medical devices, machine learning and AI, and Prof. Evis Sala, who at the time was Professor of Oncological Imaging at the University of Cambridge & Addenbrooke’s Hospital. She is now Chair of Radiology at the Università Cattolica del Sacro Cuore and Director of the Advanced Radiology Centre at the Policlinico Universitario A. Gemelli, IRCCS in Rome. Prostate Intelligence™ (Pi™) is intended for use to assist the diagnosis of prostate cancer and is the company’s first product to complete regulatory approvals.

Lucida Medical is backed by investors including XTX Ventures, Prostate Cancer Research, Macmillan Cancer Support and leading radiologists and urologists. The company is currently piloting and deploing the software in the UK, Germany and Italy, and building partnerships to make Pi™ available across Europe.

https://lucidamedical.com

X: @LucidaMedical | LinkedIn: https://linkedin.com/company/lucida-medical

For more information, contact:

• Marcus Clark, Business Development Manager at Lucida Medical: clark@lucidamedical.com

[i] Macmillan Cancer Support. Cancer prevalence. Accessed January 2024.

[ii] Cancer Research UK. Prostate cancer incidence. Accessed January 2024

[iii] As per ref 1

[iv] Cancer Research UK. Prostate cancer mortality. Accessed January 2024

ENDS